ViewRay Reports Second Quarter 2020 Results
ViewRay reported second quarter 2020 results with total revenue of $14.2 million, down from $30.2 million in Q2 2019. Four new MRIdian system orders worth $24.6 million were received, compared to three orders totaling $18.1 million last year. The backlog grew to $232.2 million from $219.3 million in 2019. The company announced a 20% workforce reduction to elongate its cash runway, ending Q2 with $179.5 million in cash. Despite a net loss of $26.2 million for Q2, the company remains optimistic about future growth.
- Secured four new MRIdian system orders totaling $24.6 million.
- Increased backlog to $232.2 million, up from $219.3 million last year.
- Reduced operating expenses to $24.5 million from $29.5 million year-over-year.
- Total revenue declined to $14.2 million from $30.2 million in Q2 2019.
- Net loss increased to $26.2 million, although lower than $30.8 million in the previous year.
- Total gross profit loss of $1.0 million compared to a profit of $3.2 million last year.
CLEVELAND, July 30, 2020 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) today announced financial results for the second quarter ended June 30, 2020.
Second Quarter 2020 Highlights:
- Total revenue of
$14.2 million , primarily from two revenue units, compared to$30.2 million , primarily from five revenue units, in the second quarter of 2019. - Received four new orders for MRIdian systems totaling
$24.6 million , compared to three new orders totaling$18.1 million in the second quarter of 2019. - Total backlog was
$232.2 million as of June 30, 2020, compared to$219.3 million as of June 30, 2019. - Cash and cash equivalents were
$179.5 million as of June 30, 2020. - Announced workforce reductions of approximately
20% as well as a program designed to temporarily retain select senior leaders, including Shar Matin, while also providing an option for them to continue with the Company if certain business and financial targets are achieved.
"We received four orders for MRIdian and used
Three Months Ended June 30, 2020 Financial Results:
Total revenue for the three months ended June 30, 2020 was
Total cost of revenue for the three months ended June 30, 2020 was
Total gross profit (loss) for the three months ended June 30, 2020 was
Total operating expenses for the three months ended June 30, 2020 were
Net loss for the three months ended June 30, 2020 was
ViewRay had total cash and cash equivalents of
Six Months Ended June 30, 2020 Financial Results:
Total revenue for the six months ended June 30, 2020 was
Total cost of revenue for the six months ended June 30, 2020 was
Total gross profit (loss) for the six months ended June 30, 2020 was
Total operating expenses for the six months ended June 30, 2020 were
Net loss for the six months ended June 30, 2020 was
Conference Call and Webcast
ViewRay will hold a conference call to discuss results on Thursday, July 30, 2020 at 4:30 p.m. ET / 1:30 p.m. PT. The dial-in numbers are (844) 277-1426 for domestic callers and (336) 525-7129 for international callers. The conference ID number is 4968496. A live webcast of the conference call will be available on the investor relations page of ViewRay's corporate website at www.investors.viewray.com.
After the live webcast, a replay will remain available online on the investor relations page of ViewRay's corporate website, www.investors.viewray.com, for 14 days following the call. In addition, a telephonic replay of the call will be available until August 6, 2020. The replay dial-in numbers are (855) 859-2056 for domestic callers and (404) 537-3406 for international callers. Please use the conference ID number 4968496.
About ViewRay®
ViewRay, Inc. (Nasdaq: VRAY), designs, manufactures, and markets the MRIdian® MR-Guided Radiation Therapy System. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology, MRIdian's high-definition MR was purpose-built to address specific challenges, including beam distortion, skin toxicity, and other concerns that potentially may arise when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Private Securities Litigation Reform Act. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, the rate of new orders, upgrades, and installations, ViewRay's preliminary second quarter results and anticipated future operating and financial performance, and ViewRay's conference call to discuss its second quarter 2020 results. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to commercialize MRIdian Linac System, demand for ViewRay's products, the ability to convert backlog into revenue, the timing of delivery of ViewRay's products, the timing, length, and severity of the recent COVID-19 (coronavirus) pandemic, including its impacts across our businesses on demand, operations and our global supply chains, the results and other uncertainties associated with clinical trials, the ability to raise the additional funding needed to continue to pursue ViewRay's business and product development plans, the inherent uncertainties associated with developing new products or technologies, competition in the industry in which ViewRay operates, and overall market conditions. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to ViewRay's business in general, see ViewRay's current and future reports filed with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2019 and its Quarterly Reports on Form 10-Q, as updated periodically with the company's other filings with the SEC. These forward-looking statements are made as of the date of this press release, and ViewRay assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.
VIEWRAY, INC. Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (In thousands, except share and per share data) | ||||||||||||||||
Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
2020 | 2019 | 2020 | 2019 | |||||||||||||
Revenue: | ||||||||||||||||
Product | $ | 10,615 | $ | 27,905 | $ | 22,085 | $ | 46,779 | ||||||||
Service | 3,490 | 2,143 | 6,151 | 3,434 | ||||||||||||
Distribution rights | 119 | 119 | 238 | 238 | ||||||||||||
Total revenue | 14,224 | 30,167 | 28,474 | 50,451 | ||||||||||||
Cost of revenue: | ||||||||||||||||
Product | 12,714 | 22,814 | 25,843 | 44,847 | ||||||||||||
Service | 2,552 | 4,107 | 5,780 | 7,722 | ||||||||||||
Total cost of revenue | 15,266 | 26,921 | 31,623 | 52,569 | ||||||||||||
Gross margin | (1,042) | 3,246 | (3,149) | (2,118) | ||||||||||||
Operating expenses: | ||||||||||||||||
Research and development | 6,211 | 6,463 | 12,548 | 11,494 | ||||||||||||
Selling and marketing | 3,093 | 7,663 | 8,916 | 12,548 | ||||||||||||
General and administrative | 15,227 | 15,398 | 31,015 | 30,507 | ||||||||||||
Total operating expenses | 24,531 | 29,524 | 52,479 | 54,549 | ||||||||||||
Loss from operations | (25,573) | (26,278) | (55,628) | (56,667) | ||||||||||||
Interest income | 87 | 687 | 782 | 907 | ||||||||||||
Interest expense | (1,071) | (1,074) | (2,109) | (1,833) | ||||||||||||
Other income (expense), net | 405 | (4,133) | 3,271 | (6,566) | ||||||||||||
Loss before provision for income taxes | $ | (26,152) | $ | (30,798) | $ | (53,684) | $ | (64,159) | ||||||||
Provision for income taxes | — | — | — | — | ||||||||||||
Net loss and comprehensive loss | $ | (26,152) | $ | (30,798) | $ | (53,684) | $ | (64,159) | ||||||||
Net loss per share, basic and diluted | $ | (0.18) | $ | (0.32) | $ | (0.36) | $ | (0.66) | ||||||||
Weighted-average common shares used to compute net loss per share attributable to common stockholders, basic and diluted | 147,563,278 | 97,572,389 | 147,506,244 | 97,129,389 | ||||||||||||
VIEWRAY, INC. Consolidated Balance Sheets (Unaudited) (In thousands, except share and per share data) | ||||||||
June 30, 2020 | December 31, 2019 | |||||||
ASSETS | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 179,514 | $ | 226,783 | ||||
Accounts receivable | 22,089 | 16,817 | ||||||
Inventory | 48,197 | 55,031 | ||||||
Deposits on purchased inventory | 4,643 | 6,457 | ||||||
Deferred cost of revenue | 6,273 | 3,466 | ||||||
Prepaid expenses and other current assets | 5,568 | 3,310 | ||||||
Total current assets | 266,284 | 311,864 | ||||||
Property and equipment, net | 22,718 | 23,399 | ||||||
Restricted cash | 1,860 | 1,404 | ||||||
Intangible assets, net | 53 | 55 | ||||||
Right-of-use assets | 10,621 | 11,720 | ||||||
Other assets | 1,642 | 1,577 | ||||||
TOTAL ASSETS | $ | 303,178 | $ | 350,019 | ||||
LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | 4,852 | $ | 13,739 | ||||
Accrued liabilities | 17,361 | 21,390 | ||||||
Customer deposits | 16,047 | 9,662 | ||||||
Operating lease liability, current | 2,347 | 2,264 | ||||||
Current portion of long-term debt | 10,889 | 1,556 | ||||||
Deferred revenue, current | 16,788 | 10,457 | ||||||
Total current liabilities | 68,284 | 59,068 | ||||||
Deferred revenue, net of current portion | 3,069 | 3,553 | ||||||
Long-term debt | 44,756 | 53,995 | ||||||
Warrant liabilities | 2,072 | 5,373 | ||||||
Operating lease liability, noncurrent | 9,293 | 10,479 | ||||||
Other long-term liabilities | 1,680 | 1,377 | ||||||
TOTAL LIABILITIES | 129,154 | 133,845 | ||||||
Commitments and contingencies (Note 6) | ||||||||
Stockholders' equity: | ||||||||
Preferred stock, par value of | — | — | ||||||
Common stock, par value of | 1,466 | 1,462 | ||||||
Additional paid-in capital | 745,418 | 733,888 | ||||||
Accumulated deficit | (572,860) | (519,176) | ||||||
TOTAL STOCKHOLDERS' EQUITY | 174,024 | 216,174 | ||||||
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $ | 303,178 | $ | 350,019 | ||||
View original content to download multimedia:http://www.prnewswire.com/news-releases/viewray-reports-second-quarter-2020-results-301103395.html
SOURCE ViewRay, Inc.
FAQ
What are ViewRay's second quarter 2020 financial results?
How many orders did ViewRay receive in Q2 2020?
What was ViewRay's cash position at the end of Q2 2020?
What changes did ViewRay make to its workforce in 2020?
What is ViewRay's backlog as of June 30, 2020?
